India to Offer Dengue Vaccinations in 2026

With the world continuing to grapple for solutions to limited Dengue fever outbreaks, India may soon offer its population a proven vaccine.

In 2024, India reported over 230,000 dengue cases and 236 related fatalities.

According to reporting by The Times of India on April 28, 2025, the 'Make in India' initiative intends to offer Takeda's QDENGA® dengue vaccine in 2026.

This vaccine launch includes a collaboration with Hyderabad-based firm Biological E. Limited, which is expected to produce about 50 million QDENGA doses annually.

QDENGA (Dengue Tetravalent Vaccine [Live, Attenuated]) is an approved two-dose vaccine preventing dengue fever and/or Severe Dengue caused by any of Dengue's four serotypes.

On December 8, 2022, QDENGA became the first dengue vaccine approved in Europe for use regardless of previous exposure and without the need for pre-vaccination testing. Since then, the World Health Organization added QDENGA to its List of Prequalified Vaccines,

Currently, over 35 countries offer commercial access to the vaccine.

In the United States, Takeda announced on July 11, 2023, that the Company voluntarily withdrew the Biologics License Application for QDENGA following discussions with the U.S. Food and Drug Administration (FDA) on aspects of data collection that could not be addressed within the review cycle. 

Furthermore, during the April 2025 U.S. Centers for Disease Control and Prevention (CDC) vaccine committee meeting, QDENGA was not on the agenda.

A previously FDA-approved Dengue vaccine (Dengvaxia) was withdrawn from the market in early 2024.

As of April 2025, the CDC has identified more cases of Dengue than expected among U.S. travelers returning from outbreak countries in the Americas. The CDC recently advised clinicians to consider Dengue in patients with fever who live in or have recently traveled to areas with a risk of Dengue. 

The CDC reported on April 23, 2025, that 1,568 travel-related Dengue cases and one local case were reported in 31 jurisdictions this year. The U.S. territories of Puerto Rico and the U.S. Virgin Islands have become endemic for Dengue infections.

The CDC Travel Health Advisory, published on April 15, 2025, states that Dengue is a year-round risk in many parts of the world, and travelers to risk areas should take precautions to prevent mosquito bites.